Status:

COMPLETED

Safety and Efficacy Evaluation of a New Contact Lens Disinfecting Solution in Gas Permeable Contact Lens Wearers

Lead Sponsor:

Alcon Research

Conditions:

Myopia

Astigmatism

Eligibility:

All Genders

Phase:

NA

Brief Summary

The purpose of this study is demonstrate substantial equivalence of an investigational contact lens disinfecting solution to a commercially available contact lens solution in gas permeable lens wearer...

Detailed Description

Subjects with normal eyes (other than correction for refractive error) successfully wearing silicone acrylate or fluoro silicone acrylate gas permeable contact lenses were randomized 2:1 to receive ei...

Eligibility Criteria

Inclusion

  • Normal eyes (other than correction for visual acuity);
  • Successful history of gas permeable contact lens wear in both eyes in one of two brands: Boston XO or Boston II;
  • Best spectacle corrected distance visual acuity greater than or equal to 20/25 in each eye;
  • Other protocol-defined inclusion criteria may apply.

Exclusion

  • Any ocular or systemic medical condition that may, in the opinion of the investigator, preclude safe administration of the investigational products or affect the results of this study;
  • Need to wear contact lenses on an extended wear basis (ie, overnight) during the study;
  • Use of a daily cleaner and/or an enzyme cleaner to care for lenses at least 7 days prior to Visit 1;
  • History of intolerance or hypersensitivity to any component of the investigational products;
  • Use of all over-the-counter (OTC) or prescribed topical ocular medications within 7 days prior to Visit 1;
  • Moderate, severe, abnormal, or other ocular findings;
  • Current or history of ocular infection, severe inflammation, or disease within 6 months prior to Visit 1;
  • Any systemic disease at Visit 1 (including allergies, respiratory infections or colds) that may affect the eye or be exacerbated by use of contact lenses or contact lens solutions;
  • Use of systemic medications that may contribute to adverse ocular effects unless on a stable dosing regimen;
  • Ocular surgery within the last 12 months;
  • Other protocol-defined exclusion criteria may apply.

Key Trial Info

Start Date :

November 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2014

Estimated Enrollment :

112 Patients enrolled

Trial Details

Trial ID

NCT01912781

Start Date

November 1 2013

End Date

May 1 2014

Last Update

June 30 2015

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.